Post-translational modification of TRAIL receptor type 1 on various tumor cells and the susceptibility of tumors to TRAIL-induced apoptosis

Biochemical and Biophysical Research Communications

Volumn 395, Issue 2, 2010, Pages 251-257

  Lin, Zhezhu ^a,b   Jin, Aishun ^a   Ozawa, Tatsuhiko ^a   Tajiri, Kazuto ^a   Obata, Tsutomu ^c   Ishida, Isao ^d   Jin, Feng ^b   Kishi, Hiroyuki ^a   Muraguchi, Atsushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b First Affiliated Hospital   (China)

^c TOYAMA INDUSTRIAL TECHNOLOGY CENTER   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Apoptosis; Epitope; Monoclonal antibodies; TRAIL; TRAIL receptor type 1

Indexed keywords

DEATH RECEPTOR 4; EPITOPE; MONOCLONAL ANTIBODY; TRI 272 ANTIBODY; TRI 404 ANTIBODY; TRI 407 ANTIBODY; TRI 412 ANTIBODY; TRI 416 ANTIBODY; TRI 417 ANTIBODY; TRI 419 ANTIBODY; TRI 422 ANTIBODY; TRI 438 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROCESSING; TUMOR CELL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; EPITOPES; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951622836     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.175     Document Type: Article

References (18)

1. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
2. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A., Goodwin R.G., and Rauch C.T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (1997) 5386-5397
3. Holoch P.A., and Griffith T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol. 625 (2009) 63-72
4. Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M., Kelley R.F., Ashkenazi A., and de Vos A.M. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4 (1999) 563-571
5. Mongkolsapaya J., Grimes J.M., Chen N., Xu X.N., Stuart D.I., Jones E.Y., and Screaton G.R. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6 (1999) 1048-1053
6. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J., and Cohen G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65 (2005) 11265-11270
7. Cha S.S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C., Sung Y.C., and Oh B.H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11 (1999) 253-261
8. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 (2007) 1070-1077
9. Clancy L., Mruk K., Archer K., Woelfel M., Mongkolsapaya J., Screaton G., Lenardo M.J., and Chan F.K. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 102 (2005) 18099-18104
10. Jin A., Ozawa T., Tajiri K., Obata T., Kondo S., Kinoshita K., Kadowaki S., Takahashi K., Sugiyama T., Kishi H., and Muraguchi A. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat. Med. 15 (2009) 1088-1092
11. Ishida I., Tomizuka K., Yoshida H., Tahara T., Takahashi N., Ohguma A., Tanaka S., Umehashi M., Maeda H., Nozaki C., Halk E., and Lonberg N. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4 (2002) 91-102
12. Yoshida T., Shiraishi T., Horinaka M., Wakada M., and Sakai T. Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol. Rep. 18 (2007) 1239-1242
13. Nakano T., Matsui T., and Ota T. Benzyl-alpha-GalNAc inhibits sialylation of O-glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. Anticancer Res. 16 (1996) 3577-3584
14. Jin Z., McDonald III E.R., Dicker D.T., and El-Deiry W.S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279 (2004) 35829-35839
15. Rossin A., Derouet M., Abdel-Sater F., and Hueber A.O. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem. J. 419 (2009) 185-192 (2 p following 192)
16. Lee H.W., Lee S.H., Ryu Y.W., Kwon M.H., and Kim Y.S. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem. Biophys. Res. Commun. 330 (2005) 1205-1212
17. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37 (2007) 101-107
18. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., de Vos A.M., and Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 (2000) 633-640